Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
0 hedge funds and large institutions have $0 invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2021 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $13K → $0 (-$13K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | -$13K | -62,507 | Closed |
|
APOPW Hedge Fund Activity: Q3 2021 in Review
0 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q3 2021, worth a combined $0 — down 100% from $13K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of APOPW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $13K sold.
- 0 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q3 2021, down from 1 in Q2 2021.
- Funds reported $0 of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q3 2021, down 100% quarter-over-quarter.
- 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q3 2021 and 1 closed out, a net change of -1 holder.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs seller in Q3 2021 was UBS Group, an estimated $13K sold.
Based on aggregated 13F filings for Q3 2021.